← Eichor
Study identifier: NCT07018648 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Safety and Efficacy Testing of a Medical Device Kardi Ai, an ECG Telemetry Monitoring System

Condition: Atrial Fibrillation (AF) · Atrial Premature Complexes · Ventricular Premature Complexes  ·  Sponsor: KARDI AI Technologies s.r.o.

PhaseNA
Planned participants115
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to evaluate the safety and efficacy of medical device Kardi Ai, an ECG telemetry monitoring device in adult population. The main questions it aims to answer are: * What is the sensitivity and specificity of Kardi Ai device for all monitored heart rythm disorders (combined) * What is the sensitivity and specificity of Kardi Ai device for each of the monitored heart rythm disorders * What is the quality of the ECG recordings Participants will receive Kardi Ai medical device. They will use it to collect ECG recordings from at least 5 different days and in total collect records of at least 10 hours duration.

This description comes directly from the study's public registry record.

Talk to the study team

David Skála  ·  +420 779 998 100  ·  david@kardi.ai

Always discuss trial participation with your own doctor first.

Locations (2)

Fakultní nemocnice OlomoucOlomouc, Czechia, CzechiaRecruiting
Fakultní nemocnice OstravaOstrava, Czechia, CzechiaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07018648